We're ready for scrutiny.

When launching a big project, especially one that runs counter to conventional thinking, scrutiny is the nicest way to describe how you should expect to be received.

I think of Ignaz Semelweiss' battle to establish handwashing as a way to prevent surgical infections. He proved the point but failed to persuade the field (fortunately Louis Pasteur was better communicator 20 years later and successful).

I recall how the founders of BlackBerry made our world of messaging a reality by moving from the conventional central computer supporting millions and millions of clients (the handheld devices) because that standard architecture could support only a limited number of handhelds. They made the handhelds the servers and the central computer the single client. Then it worked.

I'm amazed by the work of Barry Marshall and Robin Warren who believed that a common cause of gastritis (inflamed lining of the stomach) was a bacterial infection. Without much support or interest from others, Dr. Marshall underwent several endoscopies, before and after infecting himself with the bacteria and then again after treatment with antibiotics, showing the bacterial caused gastritis and antibiotics eliminated the bacteria and allowed the stomach lining to heal.

These visionaries are inspiring. Their work proved to be correct despite the scrutiny from the experts of the day.

Right Brain Bio's Vision

Pursuing a new therapy is justified when data show evidence for the biologic target matching the therapy. The justification grows when the new therapy is shown in laboratory studies to reverse disease pathology in models of that disease.

We are the first to report on the amount of dopamine inside the neurons of people with Parkinson's. And those levels are markedly elevated (not because of taking dopaminergic therapies). We published a review showing how our therapeutic (RB-190) reverses pathology in 9 models of disease.

Clinical trials are justified and the scrutiny we face is usually from those who have not spent the time looking at the data or who are unable to show data that conflicts with our observations.

An Investor's Diligence

To invest in a specialized and contrarian (or visionary) approach as ours is difficult even with scientific expertise and drug development experience. One of our investors decided to evaluate the strength and believability of our approach using an AI engine. He fed in the transcript of my recent appearance on No Silver Bullet 4 PD (video or audio) to Grok, focusing on our peer-reviewed publication of elevated dopamine inside the neurons to toxic levels.